Published in Pharmacotherapy on April 07, 1995
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. J Immunother Cancer (2014) 0.76
In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci (2012) 0.76
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep (1985) 1.15
Correlations between leukocyte count and absolute granulocyte count in patients receiving cancer chemotherapy. Cancer (1985) 0.98
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res (1988) 0.85
Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer (1986) 0.84
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep (1983) 0.81
Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat Rep (1982) 0.81
Phase I clinical trial of carbetimer. Cancer Res (1988) 0.81
Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res (1985) 0.80
Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Pharmacoeconomics (1999) 0.79
Idarubicin: a second-generation anthracycline. DICP (1991) 0.77
Phase I trial of ICRF-187 by 48-hour continuous infusion. Cancer Treat Rep (1981) 0.76
A phase I clinical and pharmacokinetic trial of hepsulfam. Cancer Res (1991) 0.76
Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res (1982) 0.75
Phase I trial of PCNU administered by 5-day courses. Cancer Treat Rep (1981) 0.75
Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha. JPEN J Parenter Enteral Nutr (1994) 0.75
New anticancer agents. Cancer Chemother Biol Response Modif (1987) 0.75
New anticancer agents. Cancer Chemother Biol Response Modif (1988) 0.75
New anticancer agents. Cancer Chemother Biol Response Modif (1990) 0.75
Fax technology for collecting outcomes data in a computer database. Am J Health Syst Pharm (1999) 0.75
Procedure costs and outcomes associated with pharmacologic management of peripheral arterial disease in the Department of Defense. Clin Ther (1999) 0.75